Ask AI

IDWeek 2026: What It Means for Latin America

Conference Coverage Clinical Thought
Conference Coverage Clinical Thought Start Activity

Released: November 19, 2026

See Activity Collection

IDWeek 2026 highlighted important innovations in HIV treatment and prevention. But the success of these innovations will depend on equitable access, sustainable healthcare systems and research that addresses regional priorities. Read on for my perspective on how scientific innovation and effective implementation must advance together to achieve equitable, sustainable, HIV care in Latin America and beyond.

IDWeek 2026 Latin America

IDWeek 2026, held in Washington, DC, highlighted important developments in HIV treatment and prevention. In the context of Latin America, where the acquisition of new cases of HIV remains a significant challenge despite the expansion of antiretroviral access, the most relevant question is not only what new interventions can achieve, but also how they can be implemented equitably across diverse healthcare systems.

Real-world Evidence for Long-acting Injectables
The importance of real-world evidence in this context cannot be overstated. The OPERA cohort, including nearly 8000 individuals switching to injectable cabotegravir/rilpivirine, demonstrated high rates of sustained virologic suppression and treatment persistence. For Latin America, where access to long-acting antiretroviral therapy remains very scarce, these findings reinforce the need to develop implementation strategies tailored to local healthcare systems; the sooner, the better.

Another significant area of focus was HIV prevention. A series of presentations examined the early adoption of twice-yearly lenacapavir for pre-exposure prophylaxis (PrEP), alongside real-world experience with injectable cabotegravir. These presentations highlighted opportunities to expand prevention choices. However, the availability of new technologies does not automatically translate into population-level impact. It is vital to acknowledge that a number of issues remain of critical importance to our Latin America region. These include affordability, regulatory approval, laboratory monitoring, healthcare infrastructure, and equitable access.

Perspectives From Latin America
Research conducted in Latin America provided particularly relevant perspectives. Investigators from Argentina presented work on missed opportunities for HIV testing, PrEP awareness, and simplified antiretroviral dispensing. Studies from the Dominican Republic explored HIV self-testing, health literacy, and PrEP engagement. These contributions remind us that improving HIV outcomes requires more than new medications: it also demands effective, accessible, and patient-centered services.

The importance of sustained engagement in care was further emphasized by regional research examining late presentation, AIDS-related mortality, and long-term outcomes. Despite remarkable therapeutic progress, preventable deaths continue to occur, particularly among individuals diagnosed late or experiencing interruptions in care. Strengthening early diagnosis, rapid treatment initiation, and retention must therefore remain priorities alongside innovation.

IDWeek 2026 also demonstrated the growing visibility of Latin American investigators within the broader infectious diseases community. By my count, the regional participation comprised 154 posters presented by Latin American investigators, another 44 with regional coauthors, and 78 colleagues involved in 23 scientific sessions, oral presentations, Fellows' Day activities, and the ID women session. Once again, Latin America has researchers whose voices are heard at the world's most important conferences. This presence is encouraging, but sustained efforts are required to broaden the scope of opportunities for early career researchers and to enhance regional representation in the international arena of scientific leadership.

Ultimately, the message for Latin America is that scientific innovation and effective implementation must advance together. New antiretroviral and prevention strategies offer important opportunities, but their success will depend on equitable access, sustainable healthcare systems, and research that addresses regional priorities. Latin America must contribute not only to implementing global advances, but also to generating the evidence that shapes the future of HIV care.

Your Thoughts
What would more equitable HIV care look like in your region, in terms of access to expanded choice for treatment and prevention? Leave a comment to join the discussion!